Targeting a brain protein pathway to protect neurons in Parkinson's disease
Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease
This research tests whether lowering a protein called FBW7 can raise protective PGC-1α levels in brain cells to help people with Parkinson's disease keep their neurons healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11264901 on NIH RePORTER |
What this research studies
Researchers will study how a cell-cleanup process called chaperone-mediated autophagy (CMA) controls the FBW7 protein and in turn PGC-1α, a key protector of mitochondria in nerve cells. The team will use lab models including mice and cell systems and analyze human brain tissue findings that show altered FBW7 in some Parkinson's patients. The work focuses on gently restoring PGC-1α levels rather than overexpressing it, because too much PGC-1α can harm dopamine neurons. Findings could point to drugs or other approaches that adjust CMA or FBW7 to keep neurons alive longer.
Who could benefit from this research
Good fit: People with Parkinson's disease, especially those with parkin (PRKN) mutations or early-stage disease, would be the most relevant group for related future studies.
Not a fit: People without Parkinson's disease or those with very advanced Parkinson's where most dopamine neurons are already lost are unlikely to get direct benefit from these preclinical experiments.
Why it matters
Potential benefit: If successful, this could lead to new therapies that protect dopamine neurons and slow progression of Parkinson's disease.
How similar studies have performed: Prior lab studies show PGC-1α can protect neurons but that high-level overexpression is harmful, and early preclinical data support targeting the FBW7/CMA pathway as a novel approach.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Simon, David K. — Beth Israel Deaconess Medical Center
- Study coordinator: Simon, David K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.